A Nordic-Baltic perspective on indications for proton therapy with strategies for identification of proper patients

References

• Particle Therapy Co-Operative Group. 2020; [cited 2020 July 1]. Available from: https://ptcog.ch.
   Google Scholar
• Durante M, Paganetti H. Nuclear physics in particle therapy: a review. Rep Prog Phys. 2016;79(9):096702.
   PubMed Web of Science ®Google Scholar
• Paganetti H. Relating proton treatments to photon treatments via the relative biological effectiveness-should we revise current clinical practice? Int J Radiat Oncol Biol Phys. 2015;91(5):892–894.
   PubMed Web of Science ®Google Scholar
• Karger CP, Peschke P. RBE and related modeling in carbon-ion therapy. Phys Med Biol. 2017;63(1):01TR02.
   PubMed Web of Science ®Google Scholar
• Falkmer S, Fors B, Larsson B, et al. Pilot study on proton irradiation of human carcinoma. Acta Radiol. 1962;58:33–51.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Ask A, Bjelkengren G, et al. Number of patients potentially eligible for proton therapy. Acta Oncol. 2005;44(8):836–849.
   PubMed Web of Science ®Google Scholar
• Mishra MV, Aggarwal S, Bentzen SM, et al. Establishing evidence-based indications for proton therapy: an overview of current clinical trials. Int J Radiat Oncol Biol Phys. 2017;97(2):228–235.
   PubMed Web of Science ®Google Scholar
• Brada M, Pijls-Johannesma M, De Ruysscher D. Proton therapy in clinical practice: current clinical evidence. J Clin Oncol. 2007;25(8):965–970.
   PubMed Web of Science ®Google Scholar
• Glatstein E, Glick J, Kaiser L, et al. Should randomized clinical trials be required for proton radiotherapy? An alternative view. J Clin Oncol. 2008;26(15):2438–2439.
   PubMed Web of Science ®Google Scholar
• Goitein M, Cox JD. Should randomized clinical trials be required for proton radiotherapy? J Clin Oncol. 2008;26(2):175–176.
   PubMed Web of Science ®Google Scholar
• Braunstein LZ, Warren LEG. Policy implications of proton radiation therapy: toward an evidence-based approach for implementing novel oncologic technologies. Int J Radiat Oncol Biol Phys. 2016;95(1):560–561.
   PubMed Web of Science ®Google Scholar
• Zietman AL. Can proton therapy be considered a standard of care in oncology? Lessons from the United States. Br J Cancer. 2019;120(8):775–776.
   PubMed Web of Science ®Google Scholar
• Liao Z, Lee JJ, Komaki R, et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer. J Clin Oncol. 2018;36(18):1813–1822.
   PubMed Web of Science ®Google Scholar
• Lin SH, Hobbs BP, Verma V, et al. Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. J Clin Oncol. 2020;38(14):1569–1579.
   PubMed Web of Science ®Google Scholar
• Higgins KA, O'Connell K, Liu Y, et al. National cancer database analysis of proton versus photon radiation therapy in non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2017;97(1):128–137.
   PubMed Web of Science ®Google Scholar
• Yock TI, Yeap BY, Ebb DH, et al. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. Lancet Oncol. 2016;17(3):287–298.
   PubMed Web of Science ®Google Scholar
• Lee CT, Bilton SD, Famiglietti RM, et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? Int J Radiat Oncol Biol Phys. 2005;63(2):362–372.
   PubMed Web of Science ®Google Scholar
• Leeman JE, Romesser PB, Zhou Y, et al. Proton therapy for head and neck cancer: expanding the therapeutic window. Lancet Oncol. 2017;18(5):e254–e265.
   PubMed Web of Science ®Google Scholar
• Yoon M, Shin DH, Kim J, et al. Craniospinal irradiation techniques: a dosimetric comparison of proton beams with standard and advanced photon radiotherapy. Int J Radiat Oncol Biol Phys. 2011;81(3):637–646.
   PubMed Web of Science ®Google Scholar
• De Ruysscher D, Mark Lodge M, Jones B, et al. Charged particles in radiotherapy: a 5-year update of a systematic review. Radiother Oncol. 2012;103(1):5–7.
   PubMed Web of Science ®Google Scholar
• Lodge M, Pijls-Johannesma M, Stirk L, et al. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother Oncol. 2007;83(2):110–122.
   PubMed Web of Science ®Google Scholar
• Hwang EJ, Gorayski P, Le H, et al. Particle therapy tumour outcomes: an updated systematic review. J Med Imaging Radiat Oncol. 2020. DOI:10.1111/1754-9485.13021
   Web of Science ®Google Scholar
• American Medical Association. Proton beam therapy model policy. 2017; [cited 2020 Sep 01]. Available from www.astro.org.
   Google Scholar
• Kim DH, Park S, Jo K, et al. Investigations of line scanning proton therapy with dynamic multi-leaf collimator. Phys Med. 2018;55:47–55.
   PubMed Web of Science ®Google Scholar
• Mohan R, Das IJ, Ling CC. Empowering intensity modulated proton therapy through physics and technology: an overview. Int J Radiat Oncol Biol Phys. 2017;99(2):304–316.
   PubMedGoogle Scholar
• Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006;65(1):1–7.
   PubMed Web of Science ®Google Scholar
• Sakthivel V, Ganesh KM, McKenzie C, et al. Second malignant neoplasm risk after craniospinal irradiation in X-ray-based techniques compared to proton therapy. Australas Phys Eng Sci Med. 2019;42(1):201–209.
   PubMed Web of Science ®Google Scholar
• Braunstein S, Nakamura JL. Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating risk. Front Oncol. 2013;3:73.
   PubMedGoogle Scholar
• Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009;27(14):2356–2362.
   PubMed Web of Science ®Google Scholar
• Neglia JP, Robison LL, Stovall M, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006;98(21):1528–1537.
   PubMedGoogle Scholar
• Ronckers CM, Sigurdson AJ, Stovall M, et al. Thyroid cancer in childhood cancer survivors: a detailed evaluation of radiation dose response and its modifiers. Radiat Res. 2006;166(4):618–628.
   PubMed Web of Science ®Google Scholar
• Schneider U, Hälg R. The impact of neutrons in clinical proton therapy. Front Oncol. 2015;5:235.
   PubMed Web of Science ®Google Scholar
• Stensvold E, Stadskleiv K, Myklebust T, et al. Unmet rehabilitation needs in 86% of Norwegian paediatric embryonal brain tumour survivors. Acta Paediatr. 2020;109(9):1875–1886.
   PubMed Web of Science ®Google Scholar
• Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–1582.
   PubMed Web of Science ®Google Scholar
• Kahalley LS, Peterson R, Ris MD, et al. Superior intellectual outcomes after proton radiotherapy compared with photon radiotherapy for pediatric medulloblastoma. J Cin Oncol. 2020;38(5):454–461.
   PubMed Web of Science ®Google Scholar
• McBride KA, Ballinger ML, Killick E, et al. Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol. 2014;11(5):260–271.
   PubMed Web of Science ®Google Scholar
• Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol. 2006;24(16):2570–2575.
   PubMed Web of Science ®Google Scholar
• Caruso J, Shulman DS, DuBois SG. Second malignancies in patients treated for Ewing sarcoma: A systematic review. Pediatr Blood Cancer. 2019;66(11):e27938.
   PubMed Web of Science ®Google Scholar
• Inskip PD, Curtis RE. New malignancies following childhood cancer in the United States, 1973-2002. Int J Cancer. 2007;121(10):2233–2240.
   PubMed Web of Science ®Google Scholar
• Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337(14):949–955.
   PubMed Web of Science ®Google Scholar
• Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338(25):1798–1804.
   PubMed Web of Science ®Google Scholar
• Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373(9660):301–308.
   PubMed Web of Science ®Google Scholar
• Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–1123.
   PubMed Web of Science ®Google Scholar
• Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144–1153.
   PubMed Web of Science ®Google Scholar
• Weber DC, Malyapa R, Albertini F, et al. Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy. Radiother Oncol. 2016;120(1):169–174.
   PubMed Web of Science ®Google Scholar
• Lambrecht M, Eekers DBP, Alapetite C, et al. Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus. Radiother Oncol. 2018;128(1):26–36.
   PubMed Web of Science ®Google Scholar
• Haslund CA, Kristensen TO, Dahlrot R, et al. Nationale retningslinjer for proton behandling. 2018; [cited 2020 Sep 01]. Available from http://www.dnog.dk.
   Google Scholar
• Langendijk JA, Lambin P, De Ruysscher D, et al. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol. 2013;107(3):267–273.
   PubMed Web of Science ®Google Scholar
• Peeters A, Grutters JP, Pijls-Johannesma M, et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol. 2010;95(1):45–53.
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Ekman M, Ericsson SR, et al. Proton therapy of cancer: potential clinical advantages and cost-effectiveness. Acta Oncol. 2005;44(8):850–861.
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Ekman M, Ericsson SR, et al. Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma. Cancer. 2005;103(4):793–801.
   PubMed Web of Science ®Google Scholar
• Mailhot Vega R, Kim J, Hollander A, et al. Cost effectiveness of proton versus photon radiation therapy with respect to the risk of growth hormone deficiency in children. Cancer. 2015;121(10):1694–1702.
   PubMed Web of Science ®Google Scholar
• Schroeck FR, Jacobs BL, Bhayani SB, et al. Cost of new technologies in prostate cancer treatment: systematic review of costs and cost effectiveness of robotic-assisted laparoscopic prostatectomy, intensity-modulated radiotherapy, and proton beam therapy. Eur Urol. 2017;72(5):712–735.
   PubMed Web of Science ®Google Scholar
• Marteinsdottir M, Paganetti H. Applying a variable relative biological effectiveness (RBE) might affect the analysis of clinical trials comparing photon and proton therapy for prostate cancer. Phys Med Biol. 2019;64(11):115027.
   PubMed Web of Science ®Google Scholar